{"id":834337,"date":"2025-04-07T07:04:34","date_gmt":"2025-04-07T11:04:34","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/"},"modified":"2025-04-07T07:04:34","modified_gmt":"2025-04-07T11:04:34","slug":"ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/","title":{"rendered":"iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline"},"content":{"rendered":"
\n

\n Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days<\/em>\n <\/p>\n

\n Additional interim in vivo data for a first-in-class Activin E antibody shows muscle sparing weight loss alone and in combination with a GLP-1 receptor agonist <\/em>\n <\/p>\n

\n iBio remains on track to submit a regulatory submission for IBIO-600 in Q1 2026<\/em>\n <\/p>\n

SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) — iBio, Inc<\/a>. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced data from a non-GLP non-human primate (NHP) pharmacokinetics (PK) study suggesting IBIO-600, the company\u2019s novel lead asset and a potentially best-in-class long-acting anti-myostatin antibody designed for subcutaneous administration, could provide a significantly extended half-life in humans and a weight loss treatment option while preserving and promoting muscle growth.<\/p>\n

The results were observed in a recently completed exploratory study in obese and elderly NHPs designed to analyze the potential of IBIO-600 in NHPs in order to closely mimic the human obese patient population by determining the antibody\u2019s half-life in serum and evaluating changes in lean and fat mass. The study consisted of two dose levels, a low dose of 5 mg\/kg and a high dose of 50 mg\/kg, with a single administration in each case. In addition to monitoring PK in serum, the study analyzed body composition changes over time by employing DEXA scans, measuring lean and fat mass.<\/p>\n

Despite the study not being powered to demonstrate statistical significance, and only having a single administration of the antibody, the results indicate IBIO-600 promoted a dose-dependent increase in lean mass and a reduction in fat mass from baseline values. The effect peaked after 8 weeks, when the NHPs receiving the low-dose had a 3.1% (163g) <\/strong>increase in lean mass and a 5.1% (270g) <\/strong>increase in the NHPs receiving the high-dose.<\/p>\n

Standard PK calculations indicated the half-life of IBIO-600 in NHPs was 40 to 52 days. <\/strong>By using multiple allometric scaling approaches1<\/sup>,2<\/sup>, the half-life in humans of IBIO-600 has an estimated range of 57-130 days. This extended half-life could potentially enable a once every 3 to 6-month dosing schedule and positions IBIO-600 as a best-in-class therapeutic for muscle preservation and high-quality weight loss.<\/p>\n

\u201cThe promising data suggest IBIO-600 could possibly exhibit the longest half-life among any other anti-myostatin candidates \u2014 potentially leading to best-in-class muscle preservation and growth with a significantly reduced dosing burden for patients with a few doses a year,” said Martin Brenner, Ph.D., DVM, iBio\u2019s CEO and Chief Scientific Officer. “IBIO-600\u2019s extended half-life and muscle-building potential make it a transformative candidate for high-quality weight loss, further strengthening our expanding cardiometabolic and obesity pipeline. It is truly remarkable we\u2019ve been able to advance this potentially best-in-class long-acting anti-myostatin antibody\u00a0to clinical candidate selection in under a year and remain fully on track for a regulatory submission in Q1 2026. This incredibly rapid progress highlights our commitment to accelerating innovation and redefining obesity treatment with cutting-edge therapeutics.\u201d<\/p>\n

iBio is also pleased to announce preclinical data for a first-in-class Activin E antibody disclosed in January<\/a>,<\/a> highlighting its potential as a novel treatment for obesity. The antibody effectively blocks Activin E signaling in human adipocytes and is currently being evaluated in an exploratory study with obese mice, both as a monotherapy with bi-weekly dosing and in combination with semaglutide dosed daily. After only two weeks of dosing, monotherapy resulted in fat-selective weight loss of approximately 4%, with a significant 18% reduction in total body fat compared to placebo. Notably, when combined with semaglutide, the Activin E antibody demonstrated a strong synergistic effect, enhancing total weight loss by an additional 9% beyond GLP-1 therapy alone, leading to an overall weight reduction of 34%. This combination also resulted in a remarkable 72% reduction in body fat over the treatment period, as measured by DEXA scans. These compelling findings underscore the potential of Activin E inhibition as a transformative approach to obesity treatment, supporting further development and clinical advancement.<\/p>\n

\n 1\u00a0<\/sup>Genki Nakamura,\u00a0Kazuhisa Ozeki,\u00a0Miho Nagayasu,\u00a0Takeru Nambu,\u00a0Takayuki Nemoto,\u00a0Ken-ichi Hosoya,\u00a0Predicting Method for the Human Plasma Concentration\u2013Time Profile of a Monoclonal Antibody from the Half-life of Non-human Primates,\u00a0Biological and Pharmaceutical Bulletin,\u00a02020,\u00a0Volume 43,\u00a0Issue 5,\u00a0Pages 823-830,\u00a0Released on J-STAGE May 01, 2020,\u00a0Online ISSN 1347-5215,\u00a0Print ISSN 0918-6158,\u00a0https:\/\/doi.org\/10.1248\/bpb.b19-01042<\/a>,\u00a0https:\/\/www.jstage.jst.go.jp\/article\/bpb\/43\/5\/43_b19-01042\/_article\/-char\/en<\/a><\/p>\n

\n 2<\/sup>
\n Haraya K, Tachibana T. Translational Approach for Predicting Human Pharmacokinetics of Engineered Therapeutic Monoclonal Antibodies with Increased FcRn-Binding Mutations. BioDrugs. 2023 Jan;37(1):99-108. doi: 10.1007\/s40259-022-00566-2. Epub 2022 Nov 30. PMID: 36449140; PMCID: PMC9709760.<\/a>\n <\/p>\n

\n About iBio, Inc.<\/strong>\n <\/p>\n

\n iBio\u00a0<\/strong>(Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.\u00a0 For more information, visit\u00a0www.ibioinc.com<\/a>\u00a0or follow us on\u00a0LinkedIn<\/a>.<\/p>\n

\n FORWARD-LOOKING STATEMENTS<\/strong>\n <\/p>\n

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding non-human primate pharmacokinetics data suggesting IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days; remaining on track to submit a regulatory submission for IBIO-600 in Q1 2026; IBIO-600 providing a significantly extended half-life in humans and a weight loss treatment option while preserving and promoting muscle growth; the extended half-life potentially enabling a once every 3 to 6-month dosing schedule and positioning IBIO-600 as a best-in-class therapeutic for muscle preservation and high-quality weight loss; IBIO-600 possibly exhibiting the longest half-life among any other anti-myostatin candidates \u2014 potentially leading to best-in-class muscle preservation and growth with a significantly reduced dosing burden for patients with a few doses a year; IBIO-600\u2019s extended half-life and muscle-building potential making it a transformative candidate for high-quality weight loss, further strengthening our expanding cardiometabolic and obesity pipeline; and the potential of Activin E inhibition as a transformative approach to obesity treatment, supporting further development and clinical advancement. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of IBIO-600 to have a half-life as long as 130 days; the ability of iBio\u2019s innovative pipeline of therapeutics in cardiometabolic disease and obesity to promote healthy weight loss and muscle-building; and iBio\u2019s ability to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs; iBio\u2019s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio\u2019s ability to promote or commercialize its product candidates for specific indications; acceptance of iBio\u2019s product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio\u2019s filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2024 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.<\/p>\n

\n Corporate Contact:<\/strong>\n <\/p>\n

iBio, Inc.
Investor Relations
ir@ibioinc.com<\/a><\/p>\n

\n Media Contacts:<\/strong>\n <\/p>\n

Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com<\/a>
David.schull@russopartnersllc.com<\/a>
(858) 717-2310 or (646) 942-5604<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo data for a first-in-class Activin E antibody shows muscle sparing weight loss alone and in combination with a GLP-1 receptor agonist iBio remains on track to submit a regulatory submission for IBIO-600 in Q1 2026 SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) — iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced data from a non-GLP non-human primate (NHP) pharmacokinetics (PK) study suggesting IBIO-600, the company\u2019s novel lead asset and a potentially best-in-class long-acting anti-myostatin antibody designed for subcutaneous administration, could provide a significantly extended half-life in humans and a … <\/p>\n

Continue reading “iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-834337","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\niBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo data for a first-in-class Activin E antibody shows muscle sparing weight loss alone and in combination with a GLP-1 receptor agonist iBio remains on track to submit a regulatory submission for IBIO-600 in Q1 2026 SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) — iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced data from a non-GLP non-human primate (NHP) pharmacokinetics (PK) study suggesting IBIO-600, the company\u2019s novel lead asset and a potentially best-in-class long-acting anti-myostatin antibody designed for subcutaneous administration, could provide a significantly extended half-life in humans and a … Continue reading "iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-07T11:04:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzY3MSM2ODUxNjI4IzIwODc1NzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline\",\"datePublished\":\"2025-04-07T11:04:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\\\/\"},\"wordCount\":1392,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzY3MSM2ODUxNjI4IzIwODc1NzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\\\/\",\"name\":\"iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzY3MSM2ODUxNjI4IzIwODc1NzM=\",\"datePublished\":\"2025-04-07T11:04:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzY3MSM2ODUxNjI4IzIwODc1NzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzY3MSM2ODUxNjI4IzIwODc1NzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/","og_locale":"en_US","og_type":"article","og_title":"iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline - Market Newsdesk","og_description":"Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo data for a first-in-class Activin E antibody shows muscle sparing weight loss alone and in combination with a GLP-1 receptor agonist iBio remains on track to submit a regulatory submission for IBIO-600 in Q1 2026 SAN DIEGO, April 07, 2025 (GLOBE NEWSWIRE) — iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced data from a non-GLP non-human primate (NHP) pharmacokinetics (PK) study suggesting IBIO-600, the company\u2019s novel lead asset and a potentially best-in-class long-acting anti-myostatin antibody designed for subcutaneous administration, could provide a significantly extended half-life in humans and a … Continue reading \"iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-07T11:04:34+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzY3MSM2ODUxNjI4IzIwODc1NzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline","datePublished":"2025-04-07T11:04:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/"},"wordCount":1392,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzY3MSM2ODUxNjI4IzIwODc1NzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/","name":"iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzY3MSM2ODUxNjI4IzIwODc1NzM=","datePublished":"2025-04-07T11:04:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzY3MSM2ODUxNjI4IzIwODc1NzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzY3MSM2ODUxNjI4IzIwODc1NzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ibio-announces-ibio-600-non-human-primate-data-showing-extended-half-life-and-muscle-growth-and-interim-in-vivo-results-for-first-in-class-activin-e-antibody-advancing-cardiometabolic-and-obesity-pi\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/834337","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=834337"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/834337\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=834337"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=834337"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=834337"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}